We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App





Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021

By LabMedica International staff writers
Posted on 23 Jun 2021
Print article
Image: Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021 (Photo courtesy of Randox Laboratories)
Image: Randox Showcases Latest Product Portfolio and Services at MEDLAB Middle East 2021 (Photo courtesy of Randox Laboratories)
Randox Laboratories (Crumlin, UK) shared a wealth of new products and innovative technologies with the industry at the 2021 edition of MEDLAB Middle East.

Randox has developed a range of new tests for COVID-19 (SARS-CoV-2) targeting genes in line with WHO & CDC recommendations. Utilizing Patented Biochip Technology, with results available from the Vivalytic, Evidence Investigator and Randox Discovery, capable of detecting both SARS-CoV-2 and Sarbecovirus (confirmatory target), to report SARS-CoV-2 positive patient samples. The Vivalytic, Evidence Investigator and Randox Discovery platforms were on display at this year’s MEDLAB Middle East.

Randox also showcased its new benchtop lab - Randox Discovery - an exciting and unique analyzer consolidating molecular and immunoassay workflows onto one compact benchtop platform. The COVID-19 diagnostic analyzer is the first to combine sample preparation techniques including extraction, PCR & Biochip Technology. Simple and easy to use, the intuitive user-interface guides the operator through the entire testing process. Built with the user and laboratory in mind, a single operator is all that is required to run up to three fully automated discovery platforms increasing operator walkaway time and ensuring rapid turnaround time of three hours to first batch results.

In addition, Randox presented the RX series of clinical chemistry analyzers that offer the world’s most extensive dedicated clinical chemistry test menu comprising routine chemistries, specific proteins, lipids, therapeutic drugs, drugs of abuse, antioxidants, veterinary and diabetes testing. They guarantee real cost savings through consolidation of routine and specialized tests onto a single platform. The RX series analyzers - RX MISANO, RX MONACO, RX DAYTONA+,

RX IMOLA and RX MODENA - deliver excellence in patient care, offering unrivalled precision with excellent reagent CV ranges, providing laboratories with the upmost reliability, analyser uptime and accuracy of patient results. With their extensive test menu and versatile range of analyzers, the RX series presents the ultimate in performance, functionality and efficiency with testing capabilities to suit all laboratory sizes and types. Renowned for robust hardware and intuitive software, the RX series continues to revolutionize testing in a variety of laboratory types including; Clinical Laboratories, University & Research Institutes, Veterinary Laboratories and Food & Wine Testing Laboratories.

Related Links:
Randox Laboratories

Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
β-Carotene Serum Control
β-Carotene in Serum/Plasma
New
Food Allergies IgG
Allerquant 42G ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: Three newly identified protein biomarkers have the potential to improve diagnostic tools for colorectal cancer (Photo courtesy of Adobe Stock)

New Protein Biomarkers to Improve Diagnostic Tools for Colorectal Cancer

Colorectal cancer is a leading cause of cancer-related deaths globally, and its incidence is expected to rise in the coming decades. This cancer begins when abnormal cells grow uncontrollably in the large... Read more

Microbiology

view channel
Image: The CRISPR-TB Blood Test provides accurate, rapid, and cost-effective diagnosis (Photo courtesy of 123RF)

CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10.6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only... Read more

Pathology

view channel
Image: The AI tool can search through data and histology images for much more precise information on cancer treatment effectiveness (Photo courtesy of Shutterstock)

AI Tool Analyzes 30K Data Points Per Medical Imaging Pixel in Cancer Search

A new artificial intelligence (AI)-powered tool can detect cell-level characteristics of cancer by analyzing data from very small tissue samples, some as tiny as 400 square micrometers, equivalent to the... Read more

Industry

view channel
Image: The game-changing immunoassay diagnostics platform delivers results from whole blood sample in 10 minutes (Photo courtesy of SpinChip)

bioMérieux Acquires Norwegian Immunoassay Start-Up SpinChip Diagnostics

bioMérieux (Marcy l’Étoile, France) has agreed to acquire SpinChip Diagnostics (Oslo, Norway), the developer of a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.